ARTICLE | Deals
Vertex adds to Type I diabetes cell therapy ambitions with $320M ViaCyte takeout
Acquisition adds tools, IP to accelerate VX-880, plus ViaCyte’s own islet cell therapy pipeline
July 11, 2022 11:44 PM UTC
Vertex is doubling down on its commitment to develop a curative cell therapy for Type I diabetes through its second acquisition in the space, this time via a takeout of ViaCyte.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced Monday it would acquire ViaCyte Inc. for $320 million in cash. The deal comes less than three years after Vertex acquired Semma Therapeutics Inc. for $950 million...